KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.
about
Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory AnalysisMolecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.Clathrin assembly protein CALM plays a critical role in KIT signaling by regulating its cellular transport from early to late endosomes in hematopoietic cells.Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Mastocytosis: a mutated KIT receptor induced myeloproliferative disorderinv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.Therapeutic targeting of c-KIT in cancer.Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.Mouse models for core binding factor leukemia.Leukemogenic potency of the novel FLT3-N676K mutant.Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia.The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia.
P2860
Q26797245-C0C513A9-370F-4161-996C-6EAF84588E77Q30252938-02CF9939-733F-443B-A6A5-D12DCB79E987Q34287371-2D4FCE42-0DA7-464A-9B77-9A9D180754F7Q34663691-509C1BC0-37E9-4A44-BA71-3C26AA498D22Q36210845-447D8685-80FD-4827-ABCE-751260D4BD1CQ36529502-D38889E1-3464-4574-AFB1-1CC1B3D907A3Q36642902-46730047-E830-4C27-860C-8092E32DB75FQ37662400-A6D0B6F1-126C-4A08-AC26-285E89996817Q38057806-CEBF4211-70EA-486D-B94E-03B43765712FQ38245417-3476887C-F0E0-4226-9DAD-05BC1067951FQ38545496-76054F67-0C64-48A9-8C9D-36C0E86AF893Q40901421-FC5710CE-FA1B-484F-820E-E4DF2DB62659Q41138171-AECE96A5-522B-485A-BE2E-2F2438040F00Q42444092-A714B01A-7D03-4645-BBCB-BB80AC848B55Q50893694-D2F45132-5EE7-4360-B75C-31F053686CCEQ53821842-4254E2E8-5D25-4459-BC63-FDC113D8A04F
P2860
KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.
@ast
KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.
@en
type
label
KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.
@ast
KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.
@en
prefLabel
KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.
@ast
KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.
@en
P2093
P2860
P1433
P1476
KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.
@en
P2093
D Gary Gilliland
Jan J Melenhorst
Lauren Brinster
Lemlem Alemu
Maggie Kench
Martha Kirby
P Paul Liu
Shelley Hoogstraten-Miller
Stacie Anderson
P2860
P304
P356
10.1182/BLOOD-2011-02-338210
P407
P577
2011-12-07T00:00:00Z